Holen Sie sich die Stockscreener-App
1.18
0.84%
-0.01
Handel nachbörslich:
1.18
Schlusskurs vom Vortag:
$1.19
Offen:
$1.21
24-Stunden-Volumen:
24,932
Relative Volume:
0.46
Marktkapitalisierung:
$29.55M
Einnahmen:
$12.00M
Nettoeinkommen (Verlust:
$-63.23M
KGV:
-0.1967
EPS:
-6
Netto-Cashflow:
$-43.02M
1W Leistung:
+0.00%
1M Leistung:
+0.85%
6M Leistung:
-33.71%
1J Leistung:
+21.65%
1-Tages-Spanne:
$1.14
$1.2155
1-Wochen-Bereich:
$1.07
$1.235
52-Wochen-Spanne:
$0.73
$2.09
Accelerate Diagnostics Inc Stock (AXDX) Company Profile
Firmenname
Accelerate Diagnostics Inc
Sektor
Branche
Telefon
303-863-8088
Adresse
3950 S. COUNTRY CLUB ROAD #470, TUCSON, AZ
Vergleichen Sie AXDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXDX
Accelerate Diagnostics Inc
|
1.18 | 29.55M | 12.00M | -63.23M | -43.02M | -6.00 |
|
ABT
Abbott Laboratories
|
134.95 | 234.06B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.39 | 154.06B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
387.92 | 148.02B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.17 | 115.71B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.76 | 42.91B | 5.72B | 4.17B | 490.10M | 6.97 |
Accelerate Diagnostics Inc Stock (AXDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-03-09 | Herabstufung | Craig Hallum | Buy → Hold |
| 2020-10-08 | Eingeleitet | BTIG Research | Neutral |
| 2020-08-07 | Hochstufung | Craig Hallum | Hold → Buy |
| 2019-09-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-11-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-05-24 | Eingeleitet | Craig Hallum | Hold |
| 2017-12-13 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-07-12 | Fortgesetzt | BTIG Research | Buy |
| 2016-03-24 | Eingeleitet | JP Morgan | Overweight |
| 2015-12-16 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Accelerate Diagnostics Inc Aktie (AXDX) Neueste Nachrichten
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com - Defense World
StockNews.com Begins Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Accelerate Diagnostics, Inc. to Host Earnings Call - ACCESS Newswire
Accelerate Diagnostics (NASDAQ:AXDX) Research Coverage Started at StockNews.com - Armenian Reporter
Axos Invest Inc. Purchases 54,293 Shares of Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA) - Armenian Reporter
Antimicrobial Susceptibility Testing Market Advancements Highlighted by Analysis and Forecast to 2033: Mark... - WhaTech
Indaba Capital Management, L.P. Acquires Significant Stake in Ac - GuruFocus.com
BD to separate biosciences and diagnostics business - BioWorld Online
Methicillin-Resistant Staphylococcus Aureus (MRSA) Testing Market Projected to Reach USD 6.5 Billion by 2035 at a 4.2% of CAGR | Future Market Insights, Inc. - Morningstar
Global Antimicrobial Resistance Surveillance Market to Reach USD 9.50 Billion by 2032, Growing at a CAGR of 5.47% - WICZ
Accelerate Diagnostics faces Nasdaq delisting risk By Investing.com - Investing.com South Africa
Accelerate Diagnostics faces Nasdaq delisting risk - Investing.com
Global Antimicrobial Susceptibility Testing Market to Reach USD 4.8 Billion by 2035, Growing at a CAGR of 3.6% | Future Market Insights, Inc. - GlobeNewswire Inc.
Accelerate Diagnostics (NASDAQ:AXDX) Share Price Passes Below 200-Day Moving Average – Time to Sell? - Defense World
Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.com - Defense World
StockNews.com Initiates Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
Accelerate Diagnostics reports preliminary FY 2024 revenue of $11.7 million - MSN
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results - PR Newswire
Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test - Business Wire
GRIFFIN ASSET MANAGEMENT, INC. Reduces Holdings in Accelerate Di - GuruFocus.com
Aptitude Secures $10M+ to Accelerate Development of Point-of-Care and Over-the-Counter CT/NG/TV STI Test on Metrix® Platform - PR Newswire
Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated by Analysts at StockNews.com - Defense World
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest Update - Defense World
Accelerate Diagnostics (AXDX) – Investment Analysts’ Weekly Ratings Changes - Defense World
Accelerate Diagnostics (NASDAQ:AXDX) Earns Hold Rating from Analysts at StockNews.com - Defense World
Antimicrobial Susceptibility Testing Market Outlook & Trends 2024: Global Forecast & Insights - WhaTech
Antimicrobial Susceptibility Testing Market Analysis - openPR
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens - Yahoo Finance
ACEL Stock Hits 52-Week High at $12.62 Amid Market Optimism - Investing.com UK
ACEL Stock Hits 52-Week High at $12.62 Amid Market Optimism By Investing.com - Investing.com South Africa
Accelerate Diagnostics director John Patience buys $314k in common stock - Investing.com Nigeria
Accelerate Diagnostics director Jack Schuler sells $314,000 in stock By Investing.com - Investing.com Nigeria
Accelerate Diagnostics director Jack Schuler sells $314,000 in stock - Investing.com India
Accelerate Diagnostics (NASDAQ:AXDX) Raised to “Hold” at StockNews.com - Defense World
Glox Therapeutics awarded grant to accelerate development of precision antibiotics - European Pharmaceutical Manufacturer
Microbial Identification Market Size, Trends, Latest Insights, Analysis and Forecast 2024-2031 - WhaTech
Sepsis Diagnostics Market To Grow at 8.5% By 2032Market.us Media - Market.us Media - United States Market News
Armistice Capital, LLC's Strategic Acquisition in Accelerate Dia - GuruFocus.com
William Blair Has Bearish Estimate for AXDX FY2024 Earnings - Defense World
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q3 2024 Earnings Call Transcript - Insider Monkey
GE HealthCare and RadNet Forge Collaboration to Transform Imaging Systems and Accelerate the Adoption of Artificial Intelligence (AI) with SmartTechnology - BioSpace
Next-generation rapid phenotypic antimicrobial susceptibility testing - Nature.com
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates - MSN
Accelerate Diagnostics: Q3 Earnings Snapshot - Houston Chronicle
Accelerate Diagnostics Reports Key Advances Amid Financial Challenges - TipRanks
Finanzdaten der Accelerate Diagnostics Inc-Aktie (AXDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):